Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Does James Flynn Think the Entry Point For Healthways, Inc. (HWAY) Has Arrived, And Should You Enter?

Page 1 of 2

According to a recent filing with the Securities and Exchange Commission, James E. Flynn‘s Deerfield Management has acquired about 2.47 million shares of Healthways, Inc. (NASDAQ:HWAY) through its affiliated funds. The holding represents about 6.91% of the $433 million healthcare company’s outstanding shares. Healthways, Inc. (NASDAQ:HWAY) is involved in engaging customer populations in healthy activities that prolong their life and also lessen their financial burden on their families and society, in terms of medical expenses. A study by the company reveals that these health risk reduction efforts can lead to an estimated ten-year savings exceeding $2 trillion. Healthways, Inc. (NASDAQ:HWAY)’s clients include corporations and health insurance companies, among other. So far this year Healthways, Inc. (NASDAQ:HWAY)’s stock has nose-dived by almost 40%. In comparison, the medical industry has appreciated by more than 13% during the same period. The latest slump in the stock price came after a sharp cut in the guidance by the company’s management this month. Revenue expectations for the year were lowered to the range of between $770 million to $785 million from a $800 million to $825 million range indicated previously. This has resulted in a $20 million impact on the company’s EBIDTA at the midpoint. The EBIDTA margin is expected to fall in the 8% to 8.5% range. The underlying factor behind these revisions was the slower than expected development in the Ornish Reversal Program and Blue Zones projects.


Flynn isn’t the only one bullish on the company. Healthways, Inc. (NASDAQ:HWAY) was in 23 hedge funds’ portfolios, who had invested a total of $285.73 million in the provider of population health management solutions at the end of March. Healthways investors should be aware of an increase in enthusiasm from smart money recently. There were 17 hedge funds in our database with holdings that had a total value of $233.78 million at the end of the previous quarter. Thus there was a notable increase in investment from the smart money during the first quarter, considering shares declined slightly during the period.

James E. Flynn
James E. Flynn
Deerfield Management

Why do we pay attention to hedge fund sentiment? Most investors ignore hedge funds’ moves because as a group their average net returns trailed the market since 2008 by a large margin. Unfortunately, most investors don’t realize that hedge funds are hedged and they also charge an arm and a leg, so they are likely to underperform the market in a bull market. We ignore their short positions and by imitating hedge funds’ stock picks independently, we don’t have to pay them a dime. Our research have shown that hedge funds’ long stock picks generate strong risk adjusted returns. For instance the 15 most popular small-cap stocks outperformed the S&P 500 Index by an average of 95 basis points per month in our back-tests spanning the 1999-2012 period. We have been tracking the performance of these stocks in real-time since the end of August 2012. After all, things change and we need to verify that back-test results aren’t just a statistical fluke. We weren’t proven wrong. These 15 stocks managed to return more than 145% over the last 34 months and outperformed the S&P 500 Index by 85 percentage points (see the details here).


Keeping this in mind, let’s go over the key action surrounding Healthways, Inc. (NASDAQ:HWAY).

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!